Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering

Benzinga Newsdesk www.benzinga.com Positive 60.5%

Neg 0% Neu 0% Pos 60.5%

Comments

No comments yet. Be the first!